Drug Profile
Research programme: MTAP-deleted cancer therapeutics - Agios/Celgene
Alternative Names: PRMT5 inhibitor - Bristol Myers SquibbLatest Information Update: 26 May 2021
Price :
$50
*
At a glance
- Originator Agios Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Apr 2021 Preclinical trials in Cancer in USA (Parenteral) before April 2021
- 10 Apr 2021 Pharmacodynamics data from a preclinical trial in cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 28 Mar 2020 No recent reports of development identified for research development in Cancer in USA (Parenteral)